Novo and Nan Fung Life Sciences are among the investors as Harmony Biosciences, which focuses on central nervous system disorders.
US-based biopharmaceutical company Harmony Biosciences closed a $270m funding round yesterday that included pharmaceutical firm Novo and Nan Fung Life Sciences, a subsidiary of property developer Nan Fung.
Financial services group Fidelity Management & Research Company also took part in the round, as did growth equity firm Valor Equity Partners and healthcare-focused investment firms HBM Healthcare Investments, Vivo Capital and VenBio Partners.
Harmony is developing drug treatments for rare and orphan diseases, particularly those which affect the central nervous system…
